Alpha Cognition Inc (ACOG) Stock Analysis

Verdict: HOLD

Aggressive insider buying and a robust cash position de-risk the path to 2028 profitability, provided ZUNVEYL captures Alzheimer's share.

Investment score: 64/100

Analysis as of

Is Alpha Cognition Inc stock worth reviewing? The TradeMates thesis

The model identifies Alpha Cognition as a high-risk, high-reward biotech play backed by institutional accumulation and a 110% upside to analyst targets. Despite current losses, the technical floor near $5.80—defended by insiders—presents a compelling entry point for a long-duration profitability trade.

7-factor investment score

Alpha Cognition Inc opportunities and risks

What speaks for ACOG

What speaks against ACOG

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
ACOGn/a8.9xn/a86.4%-232.2%-31.6%
ZYMEn/a22.8x2026.0x94.4%-126.3%-2474.4%
ENGNn/a0.0xn/a0.0%0.0%-109.6%
Peer mediann/a11.4x1012.6x47.2%-63.2%-1292.0%

Frequently asked questions about Alpha Cognition Inc (ACOG)

Is ACOG stock a good investment?

The TradeMates model rates Alpha Cognition Inc as HOLD with an investment score of 64/100. The model identifies Alpha Cognition as a high-risk, high-reward biotech play backed by institutional accumulation and a 110% upside to analyst targets. Despite current losses, the technical floor near $5.80—defended by insiders—presents a compelling entry point for a long-duration profitability trade. This is algorithmic model output, not personal investment advice.

Is ACOG stock a buy?

The TradeMates model verdict for ACOG is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.